⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
FATE News
Fate Therapeutics, Inc.
Fate Therapeutics Announces Encore Clinical Data Presentation of FT819 Off-the-Shelf CAR T-Cell Product Candidate at the CCR – West 2026 Meeting
globenewswire.com
FATE
Fate Therapeutics to Participate in Fireside Chat at the 2026 Annual Cantor Global Healthcare Conference
globenewswire.com
FATE
Fate Therapeutics Initiates Potentially Registrational RECLAIM-LN Clinical Trial of FT819 for the Treatment of Lupus Nephritis
globenewswire.com
FATE
Form 8-K
sec.gov
FATE
Fate Therapeutics Reports Second Quarter 2026 Financial Results and Business Updates
globenewswire.com
FATE
CAR T-Cell Therapy for Acute Lymphoblastic Leukemia Market to Grow Significantly at a CAGR of 6.8% During the Forecast Period (2026-2036), Driven by Emerging Therapies and Expanding Pipeline | DelveInsight
prnewswire.com
CLLS
AUTL
FATE
GILD
NVS
Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
globenewswire.com
FATE
RARE Drug Development Symposium Marks 10th Anniversary with Dedicated Pitch Sessions and The Theme and Call to Action to Align Advocates, Science and Industry
prnewswire.com
BIIB
REGN
GILD
BTE
BROS
BFLY
BCTX
BCRX
BTAI
ALRS
CAPR
CRIS
CYCN
EXAS
FATE
GNTX
HRMY
INCY
IONS
KODK
LAKE
LULU
MRNA
NBIX
NTRA
OCGN
ORGN
PGEN
PLRX
RARE
RGNX
RXRX
SAVA
SGMO
SNOW
SRPT
STEM
TGTX
TLSA
TXG
VRTX
ZETA
Fate Therapeutics Receives FDA Clearance of Investigational New Drug Application for FT839 Product Candidate
globenewswire.com
FATE
Fate Therapeutics to Present Preliminary Clinical Data of FT819 Off-the-Shelf CAR T-Cell Product Candidate for Systemic Sclerosis at the ISSCR 2026 Annual Meeting
globenewswire.com
FATE